{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:20:37Z","timestamp":1787840437669,"version":"build-2784847793"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background and aim:<\/jats:title>\n                    <jats:p>Little data is available regarding the 24-week therapy with pegylated interferon and ribavirin in Egyptian patients with hepatitis C virus (HCV) genotype 4 infection. We aimed to investigate the efficacy of 24-week versus 48-week peginterferon \u03b1-2a plus ribavirin therapy in patients with HCV genotype 4 infection with with rapid virological response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This trial included 102 patients with HCV genotype 4 infection and low viral load. They were treated with peginterferon \u03b1-2a (180 \u03bcg\/week) plus ribavirin. Patients (87\/102) with a rapid virological response were randomized for a total treatment duration of 24 weeks (group A: 43) or 48 weeks (group B:44). Virological responses (EVR: early virological response, EOTR: end of treatment response, and SVR: sustained virological response) were assessed for each group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In group A, EVR was achieved in 37\/43 (84%) patients, while EOTR was achieved in 34\/43 (79%) patients and SVR in 30\/43 (70%) patients. In group B, on the other hand EVR was achieved in 38\/44 (84%) patients, while EOTR was achieved in 35\/44 (80%) patients and SVR in 32\/44 (73%) patients. No significant difference in SVR rates was observed between the two groups. The rate of adverse events was higher in group B, with lower adherence rates than group A.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In patients with chronic HCV genotype 4 infection with rapid virological response and low viral loads, a 24-week peginterferon \u03b1-2a plus ribavirin therapy is as effective as a 48- week therapy with lower rate of adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.7869\/tg.2012.27","type":"journal-article","created":{"date-parts":[[2012,12,15]],"date-time":"2012-12-15T04:17:53Z","timestamp":1355545073000},"page":"112-117","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["A randomized trial of 24 versus 48 weeks of peginterferon \u03b1-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response"],"prefix":"10.4103","volume":"33","author":[{"given":"Hisham R El","family":"Khayat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser M","family":"Fouad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein El","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Rizk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","container-title":["Tropical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007902-201204000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:22:49Z","timestamp":1787836969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007902-201204000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.7869\/tg.2012.27","relation":{},"ISSN":["0250-636X"],"issn-type":[{"value":"0250-636X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}